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Parkinson’s disease (PD) is a progressive movement disorder with multiple non-motor
symptoms. Although family genetic mutations only account for a small proportion of the
cases, these mutations have provided several lines of evidence for the pathogenesis
of PD, such as mitochondrial dysfunction, protein misfolding and aggregation, and the
impaired autophagy-lysosome system. Recently, vesicle trafficking defect has emerged
as a potential pathogenesis underlying this disease. Rab GTPases, serving as the core
regulators of cellular membrane dynamics, may play an important role in the molecular
pathway of PD through the complex interplay with numerous factors and PD-related
genes. This might shed new light on the potential therapeutic strategies. In this review,
we emphasize the important role of Rab GTPases in vesicle trafficking and summarize
the interactions between Rab GTPases and different PD-related genes.
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INTRODUCTION
Parkinson’s disease (PD) is the second most prevalent chronic neurodegenerative disorder of
aging, clinically characterized by motor symptoms including resting tremor, muscle rigidity,
bradykinesia, postural instability and various non-motor symptoms (Shi et al., 2016). The most
evident pathological features are the progressive degeneration of dopaminergic neurons and axonal
projections in the substantia nigra and the wide spreading of eosinophilic Lewy bodies whose
cardinal component is α-synuclein detected in some surviving neurons (Goedert et al., 2013).
The etiology underlying the development of PD remains elusive. To date, approximate 18 genes
have been identified as the genetic causes for familiar PD, which have provided critical clues for
the pathogenesis of the disease (Atashrazm and Dzamko, 2016). Recently, accumulating genetic
discoveries have revealed the association between vesicle trafficking and PD (Zimprich et al., 2011;
Edvardson et al., 2012; Wilson et al., 2014). Disruption of the cellular vesicle trafficking results in
the impaired degradation of certain proteins and further leads to the abnormal protein aggregation,
which exerts a toxic effect on neurons (Mazzulli et al., 2016). Rab GTPases (Rabs) perform the basic
functions in intracellular trafficking events (Figure 1). Moreover, a series of recent studies have
revealed that certain Rabs are involved in the modulation of α-synuclein. Impairment of these
proteins have been reported to be one of the rare causes for inherited early onset PD (Wilson
et al., 2014; Lesage et al., 2015; Mata et al., 2015; Shi et al., 2016). These new findings provide a
novel insight into the molecular pathogenesis of PD. Moreover, the pathogenic mechanisms of
different PD-related genes (SNCA, LRRK2, PINK1, Parkin and TMEM230) may share a converging
molecular pathway, and Rabs may serve as potential modulators in this pathway. In this review,
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we summarize the physiological functions of Rabs and their
interactions with multiple PD-related genes (Table 1).
RABS AND THEIR ROLES IN THE
VESICLE TRAFFICKING PATHWAY
Rabs are the largest subfamily of Ras-like GTPases with more
than 60 members in the human genome and 11 members in
the yeast, serving as molecular “switches” in vesicle trafficking
(Pereira-Leal and Seabra, 2001). Generally consisting of 200
amino acids, Rabs are widely distributed across the eukaryotic
cells. They perform the essential functions in the formation,
maturation, transport, tethering and fusion of vesicles, regulating
the interactions among the major organelles and maintaining
the cellular homeostasis (Binotti et al., 2016). Some structural
features of the primary structure contribute to the specific
interactions among membranes (Pereira-Leal and Seabra, 2000;
Lipatova et al., 2015). The GTP-binding regions are highly
conserved in evolution and make Rabs present in inactive GDP-
bound and active GTP-bound forms. The CAAX boxes usually
contain two cysteine residues and facilitate the attachment of
Rabs to the membrane after prenylation. Located upstream at
CAAX boxes, the hypervariable region may enable targeting
Rabs to the specific effectors. Additionally, the Rab family
(RabF) motifs (RabFl∼RabF5) serve to differentiate Rabs from
other members of the Ras superfamily; the Rab subfamily
(RabSF) sequences play an important part in the identification
of various subfamilies (Pereira-Leal and Seabra, 2000). Some
studies indicate that apart from the diversity of C-terminal,
RabF and RabSF are also important for the specific interactions
with target effectors and membranes (Ali and Seabra, 2005).
The GTPase fold contains a six-stranded sheet and five α
helices which are interconnected by 10 loops. Different forms of
FIGURE 1 | Physiological functions of PD-related Rabs. Intracellular vesicle trafficking pathways and several related Rab GTPases are presented in the above
cell model. Rab1 facilitates endoplasmic reticulum (ER) to Golgi trafficking. Rab3, accompanied by Rab8, mediates the trafficking from trans-Golgi network (TGN) to
the plasma membrane. Rab5, serving as a key factor in the early endosome formation, is required for the transport of clathrin-dependent endosomes. Rab7 mediates
the fusion of late endosomes and lysosomes, which plays an important role in the autophagy-lysosome pathway. Rab8 and Rab10 facilitate trafficking of glucose
transporter type 4 (GLUT4) to the plasma membrane. Rab13 regulates the junctions among epithelial cells. Rab11 and Rab35 regulate the recycling endosome
trafficking. Rab7l1 plays a role in the trafficking from lysosome to TGN. Rab32 mediates the fission of mitochondria and the trafficking from TGN to melanosome.
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TABLE 1 | Parkinson’s disease-related Rab GTPases.
Rab GTPases Localization Physiological function Related genes Relevant Pathogenesis
Rab1 ER, cis-Golgi, intermediate
compartment
ER-Golgi SNCA Rescue the toxicity induced by aberrant
α-synuclein.
Rab3 Secretory vesicles, PM Exocytosis, neurotransmitter
release
SNCA, LRRK2 Colocalize with α-synuclein and regulate its
distribution. Substrate of LRRK2-mediated
phosphorylation.
Rab5 PM, CCVs, early endosome Endocytosis, early endosome
fusion
SNCA, LRRK2,
TMEM230
Colocalize with α-synuclein, LRRK2 and TMEM230.
Together with LRRK2 regulate synaptic vesicle
endocytosis.
Rab7 Late endosome, lysosomes, Late endosome to lysosome SNCA, LRRK2, Parkin,
TMEM230
Colocalize with α-synuclein and TMEM230. Reverse
the disturbance induced by LRRK2 defect in vivo
and in vitro. Involve the Parkin-mediated mitophagy.
Rab8 TGN, GLUT4-positive
vesicles
TGN-PM transport, GLUT4
trafficking
SNCA, LRRK2, PINK1 Interact with α-synuclein and alleviate the toxicity
induced by aberrant α-synuclein. Substrate of
LRRK2/PINK1-mediated phosphorylation.
Rab10 Golgi, GLUT4-positive
vesicles
Exocytosis, TGN/RE to PM,
GLUT4 trafficking
LRRK2 Substrate of LRRK2 -mediated phosphorylation.
Rab11 Golgi, recycling endosome,
early endosome
TGN/RE to PM SNCA, TMEM230 Interact with α-synuclein and modulate its
secretion. Colocalize with TMEM230.
Rab13 Tight junctions, TGN Junctions among epithelial
cells
SNCA Alleviate the toxicity induced by aberrant
α-synuclein.
Rab7L1 Lysosomes Lysosome to TGN LRRK2 Together with LRRK2 involve the trafficking from
lysosome to TGN.
Rab32 Mitochondria, melanosomes TGN to melanosome,
mitochondrial fission
LRRK2 Control LRRK2-related late endosomal events.
Rab35 PM, clathrin-coated pits,
recycling endosomes
RE to PM SNCA Promote the aggregation and secretion of A53T
α-synuclein.
Rab39b Golgi Unknown SNCA Modulate the localization of α-synuclein.
ER, endoplasmic reticulum; PM, plasma membrane; CCV, clathrin-coated vesicles; TGN, trans-Golgi network; GLUT4, Glucose transporter type 4; RE, recycling
endosome.
nucleotide-bound Rabs present distinct conformation involving
the switch I and switch II regions (Stroupe and Brunger,
2000). Through the cycle between active and inactive states,
Rabs achieve the function as molecular “switches.” The new
inactive GDP-bound form interacts with Rab escort protein
(REP) and is delivered to a geranylgeranyl transferase (GGTase)
(Alexandrov et al., 1994). After prenylation, the Rab GDP
dissociation inhibitor (GDI) recognizes the GDP-bound Rab
and regulates the specific insertion to the membrane with the
assistance of a GDI dissociation factor (GDF) (Sivars et al.,
2003). Once the Rab interacts with the target membrane,
it transforms from the GDP-bound form to the GTP-bound
form, a reaction that is catalyzed by guanine nucleotide
exchange factor (GEF) (Delprato et al., 2004). The active GTP-
bound form is recognized by the effector proteins including
sorting adaptors, tethering complexes, motor proteins and
various enzymes (Hutagalung and Novick, 2011). Followed by
hydrolysis which is stimulated by the GTPase activating protein
(GAP), the trafficking event comes to an end (Pan et al.,
2006).
Vesicle trafficking in the clathrin-dependent or clathrin-
independent manner is the core process for the cellular
membrane dynamics. Numerous Rabs are involved in the
budding, uncoating, motility and fusion of vesicles via interaction
with the relevant effectors. Once a Rab stimulates the association
between the sorting adaptor and the distinct receptor, the cargo
is shipped into a budding vesicle. Rab9, whose effector is
TIP47, facilitates the interaction between TIP47 and cytoplasmic
terminal of mannose-6-phosphate receptors (M6PRs) during
the formation of vesicles and maintains the recycle of M6PRs
from the late endosome to the trans-Golgi network (TGN)
(Aivazian et al., 2006). Coated vesicles account for most of
the membrane trafficking, and the coats are removed to allow
the fusion of vesicles. The assembly polypeptide 2 (AP2) is
crucial for the recruitment of clathrin, of which the µ2 subunit
interacts with the cargo after phosphorylation by µ2 kinase
(Jackson et al., 2003). Rab5 is involved in the regulation of vesicle
uncoating via either the removal of µ2 kinase or the turnover of
phosphatidylinositol-4, 5-biphosphate [PI (4, 5) P2] (Semerdjieva
et al., 2008). To validate the correct delivery of vesicles to the
relevant membranes, it is necessary for Rabs to mediate vesicle
trafficking along a series of motor proteins and microtubules.
For example, myosin Va is linked to Rab27 by melanophilin
working as an adaptor protein, and then delivers the relevant
vesicles to the pericellular matrix to allow melanocytes to
achieve their physiological functions (Wu et al., 2002). To ensure
the specificity of membrane fusion, Rabs may cooperate with
tethering factors and mediate interactions between vesicles and
the relevant membrane. As a result of the overlapping binding
site of endosome antigen 1 (EEA1) for Rab5 and syntaxin-6, Rabs
may interact directly with SNAREs and regulate the docking and
fusion with target membranes (Simonsen et al., 1999).
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RABS INTERACT WITH α-SYNUCLEIN
AND MODULATE ITS DISTRIBUTION
α-Synuclein is a small protein encoded by SNCA, whose role in
the pathogenesis of PD has been highly debated over the years.
Initially identified as a presynaptic protein, α-synuclein may play
an important role in endo- or exocytosis of synaptic vesicles
(Hansen et al., 2011). Recent studies revealed that α-synuclein
diffused among the cells via a prion-like transmission, and the
presence of extracellular α-synuclein challenged the previous
notion indicating that α-synuclein was limited to the cytoplasm
(El-Agnaf et al., 2003; Lee et al., 2006; Desplats et al., 2009;
Hansen et al., 2011). As for lacking a signal sequence, part
of extracellular α-synuclein has been confirmed to translocate
across the membrane via the exocytosis pathway, which relies on
calcium rather than the conventional manner, and the process is
promoted under the stressing conditions (Lee et al., 2005; Jang
et al., 2010; Emmanouilidou and Vekrellis, 2016). Additionally,
extracellular α-synuclein can also return to the neurons via
endocytosis or the clathrin-dependent manner (Liu et al., 2007;
Lee et al., 2008). All of the above studies have shed new light on
the role of α-synuclein in the pathogenesis of PD and indicate the
possible interactions between α-synuclein and Rabs which play a
critical role in modulating the vesicle trafficking.
A large number of studies have made efforts to clarify the
interactions between Rabs and α-synuclein, and this field can
be elucidated from two different perspectives. On the one hand,
by a train of immunofluorescence, co-immunoprecipitation and
other strategies, certain Rabs (Rab3a, Rab5, Rab8, Rab7, and
Rab11a) have been confirmed to interact with α-synuclein in
different models and protect cells from the toxicity induced
by the mutation or over-expression of α-synuclein (Hasegawa
et al., 2011; Chutna et al., 2014). α-Synuclein accumulation is
liable to collapse endoplasmic reticulum-Golgi trafficking during
the process of tethering or docking in a manner of dose and
time dependence, which can be alleviated by overexpression of
Ypt1/ Rab1 which helps the COPII vesicles uncoating in yeast or
dopaminergic neurons (Cooper et al., 2006; Gitler et al., 2008).
The interaction between Rab1 and α-synuclein may be mediated
by prenylated Rab acceptor protein (PRA1) which serves as a
GDF for Rab1 (Lee et al., 2011). Using a Drosophila model, Breda
et al. (2015) revealed that overexpression of Rab11 colocalizing
with α-synuclein in intracellular inclusions could significantly
reverse the synaptic potentiation at the neuromuscular junction
due to the increase of synaptic vesicle size. Through a shRNA-
based screen, some Rabs (Rab8b, Rab11a, and Rab13) have
been identified as modulators of α-Synuclein in living cells
and reduced the toxicity induced by aggregated α-synuclein via
secretion enhancement (Goncalves et al., 2016). Rab8, playing
a role in the post-Golgi trafficking, binded with the C terminal
of α-synuclein, which was confirmed by the nuclear magnetic
resonance spectroscopy. In cell models, Rab8 suppressed the
toxicity caused by mutation or overexpression of α-synuclein
(Yin et al., 2014). On the other hand, Rabs may be involved in
regulating the recycling and distribution of α-synuclein, which
opens a new window for new therapeutic strategies. Apart
from degradation by the lysosomal pathway, the internalized
extracellular α-synuclein might be partly secreted from cells
via exocytosis, which might be facilitated by Rab11 (Liu et al.,
2009; Chutna et al., 2014). Chutna et al. (2014) conducted a
further study that showed the co-localization of Rab11 and
α-synuclein in vivo. In addition, they also found that Rab11
rescued the α-synuclein aggregation and cytotoxicity. However,
the mechanism underlying how Rab11 regulates the secretion of
α-synuclein is still disputed (Chutna et al., 2014). Besides, the
downregulation of the novel disease-causing gene Rab39b results
in the dysregulation of α-synuclein homeostasis, which will be
extensively elucidated below (Wilson et al., 2014). As a protein
regulating synaptic vesicles, Rab3a not only has been confirmed
to have a close association with α-synuclein but also may lead
to the re-distribution of α-synuclein via a conformation change
(Chen et al., 2013). Recently, Rab35 was identified as a potential
biomarker in the serum for the differential diagnosis and
progression of PD. Besides, the functional study also suggested
that overexpression of Rab35 led to increased aggregation and
secretion of aberrant α-synuclein (Chiu et al., 2016). Above all,
these lines of evidence suggest that the α-synuclein pathology
propagation may partly attribute to the dysregulation of Rabs.
THE INTERACTIONS BETWEEN RABS
AND DIFFERENT PD-RELATED GENES
Leucine-Rich Repeat Kinase 2
Leucine-rich repeat kinase 2 (LRRK2, also known as PARK8) is
a multi-domain 280 kDa protein characterized with functional
GTPase and kinase domains (Kang and Marto, 2016). Most
PD-specific mutations of LRRK2 occur in the afore-mentioned
regions and lead to autosomal recessive and several sporadic
PD, which hints at the importance of these enzymes in the
pathogenesis (Funayama et al., 2005; Gilks et al., 2005; Kachergus
et al., 2005; Tan et al., 2007; Martin et al., 2014). LRRK2 is
involved in diverse cellular molecular events, such as synaptic
vesicle dynamic, mitochondrial function and autophagy (Plowey
et al., 2008; Shin et al., 2008; Wang et al., 2012). To support
the role of LRRK2 in vesicle trafficking, there are a few lines
of evidence suggesting the complex interactions between LRRK2
and certain Rabs.
Since the identification of the first LRRK2-related Rab GTPase,
Rab5b, involved in synaptic vesicle endocytosis, effort has
been made to investigate the novel interactive GTPases (Shin
et al., 2008). Lrrk, a homolog of human LRRK2 in Drosophila,
interacted strikingly with Rab7 and regulated the localization
of lysosome (Dodson et al., 2012). Besides, this study also
linked the pathogenesis underlying LRRK2 G2019S to the
disturbance of Rab7-mediated lysosome positioning (Dodson
et al., 2012). Another study also identified that the impaired
trafficking from early to late endosomes induced by the mutation
of LRRK2 could be alleviated by coexpression of Rab7, which
deepened the understanding of the interaction between LRRK2
and Rab7 (Gomez-Suaga et al., 2014). Using the transcriptomic
approach, LRRK2 has been reported to bind with Rab7l1 whose
polymorphism confers the reduced risk of PD at the Golgi
apparatus, and the degeneration induced by G2019S could be
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rescued by the overexpression of the Rab7l1 in the Drosophila
dopamine neurons (Gan-Or et al., 2012). Furthermore, in the
case of LRRK2 mutation or Rab7l1 knockdown, the retromer
pathway components levels including VPS35 appeared reduced,
which suggested that LRRK2 or Rab7l1 might be involved in
the retromer pathway (MacLeod et al., 2013). Besides, Steger
et al. used the approach of high-resolution quantitative mass
spectrometry and combined it with other approaches to identify
the substrates of LRRK2. However, only two sites met the
strict criteria: pSer935 in LRRK2 and pThr73 of the small
GTPase Rab10. In the following study, they also found the
phosphorylation of some Rabs (Rab3, Rab8), which contained
a Thr at the site equivalent to T73-Rab10 in vitro and in vivo.
Interestingly, all of the above sites were in the switch II region
which mediated the cycle of GDP/GTP for the interaction with
the cellular membrane. Overexpression of LRRK2, to some
extent, might lower the affinity of some Rabs to the GDIs and
caused the abnormal insertion to the membrane and disruption
of the vesicle trafficking (Steger et al., 2016). It appears that Rabs
work as a downstream regulator of LRRK2 to achieve their role
in vesicle trafficking. Conversely, in another study Waschbusch
et al. (2014) found that Rab32 might directly interact with the
amino terminal of endogenous LRRK2 and influenced LRRK2-
related late endosomal events. Taken together, the physiological
function of LRRK2 in vesicle trafficking is closely associated with
Rabs and the dysfunction of either of the components may result
in a defect in vesicle dynamics, which could ultimately lead to PD.
PTEN-Induced Kinase 1/Parkin
Loss-of-function mutations in the PTEN-induced kinase 1
(PINK1) and RBR E3 ubiquitin protein ligase (Parkin) usually
lead to autosomal recessive PD (Kitada et al., 1998; Valente et al.,
2004). It has been reported that PINK1 worked as the upstream
regulator of Parkin in a common pathway and was linked to the
mitochondrial quality control. Once mitochondrial dysfunction
is detected by PINK1, Parkin is recruited to ubiquitinate the
damaged mitochondrial and clear them up via autophagy
(Narendra et al., 2008, 2010; Ziviani et al., 2010). PD patients
with PINK1 or Parkin defects usually exhibit similar phenotypes.
However, Dave et al. (2014) observed that knockout of Parkin
in rats did not cause so serious neurodegeneration as PINK1,
which implicated that additional proteins might share a common
pathway (Khan et al., 2002). A few investigations suggest that
Rabs are candidate proteins to serve in downstream steps of the
mitophagy pathway. Lai et al. (2015) conducted a SILAC-based
phosphoproteomic screening to identify the novel substrates
of PINK1. They found that Ser111 of three Rab GTPases
(Rab8a, Rab8b, and Rab13) were phosphorylated in a PINK-
dependent and Parkin-independent manner. Phosphorylation
of this site in Rabs might impair the interaction with the
respective GEF, which thereby disrupted the activation of Rabs
(Lai et al., 2015). Rab7 as well as its GAP TBC1D15 and
TBC1D17 have been reported to be involved in the Parkin-
mediated mitophagy. Both TBC1D15 and TBCD17 played an
important role in the process of autophagosome formation and
prevented the membrane from Rab7-mediated inflation (Yamano
et al., 2014).
Transmembrane-Protein 230
Transmembrane-protein 230 (TMEM230) gene presumably
encodes a transmembrane protein with elusive physiological
localization and function. The latest study by Deng et al.
(2016) investigating on a large North American family has
revealed that TMEM230 was a disease-causing gene of PD with
typical pathological features of Lewy bodies. To characterize
the human TMEM230 distribution and function, a series of
confocal microscopy experiments were conducted. The results
showed that vesicle structures characterized with TMEM230
were predominantly located in the perinucleus region and
colocalized with the markers of synaptic vesicles. Given the
multiple roles of Rabs in vesicle trafficking, they also found
interactions between TMEM230 and Rab5a, Rab7 or Rab11a,
respectively. These findings, in turn, suggested that TMEM230
might play a role in the process of vesicle formation and
trafficking; the impairment of this protein might lead to
pathological features in neurons in patients with PD (Deng et al.,
2016).
Rab39b
Rab39b, first isolated from the human fetal brain, encodes
a neuron-specific protein with putative functions in the
synapse formation and maintenance (Cheng et al., 2002).
Mapping to the human chromosome Xq28, loss-of-function
mutations or increased dosage of Rab39b were confirmed to be
linked to the molecular basis of X-linked mental retardation
(Giannandrea et al., 2010). To explore the mechanism underlying
Rab39b-related cognitive deficits, there was evidence suggesting
that Rab39b regulated the alpha-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid receptor (AMPAR) arrangement in
the case of interaction with the PDZ domain of protein
interacting with C-kinase 1 (PICK1), which was important for
synaptic plasticity (Mignogna et al., 2015). Genetic analysis
of Australian and Wisconsin kindreds first identified that the
defect in Rab39b caused pathologically defined PD. Following
functional studies revealed that altered Rab39b was rapidly
metabolized through the proteasome pathway and might
dysregulate the localization of α-synuclein (Wilson et al.,
2014). Based on this novel breakthrough, a large number
of studies were conducted to further investigate the genetic
contribution of Rab39b to the pathogenesis of PD (Lesage
et al., 2015; Mata et al., 2015; Guldner et al., 2016).
Recently, our team also identified a novel mutation of Rab39b
(c.536 dup A) in a family, of which the patients displayed
juvenile parkinsonism and mental retardation syndromes.
Moreover, the brain magnetic resonance imaging (MRI) and
computed tomography (CT) scans of both patients showed
calcification in the basal ganglia, which was never reported
in the previous cases (Shi et al., 2016). According to the
latest study, the complex formed by C9ORF72, WDR41 and
SMCR8 worked as a GEF for Rab39b as well as Rab8a,
which suggested that Rab39b might be involved in the
autophagy regulation (Sellier et al., 2016). Albeit with constant
studies focusing on the characterization of Rab39b molecular
functions, the mechanisms of genetic defects still need to be
explored.
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CONCLUSION
Over the years, many researchers have paid much attention
to exploring the pathogenesis of PD to halt or slow
the progression of PD and identify effective therapeutic
strategies. Different hypothesizes have been proposed, such as
mitochondrial dysfunction, protein misfolding and aggregation,
and impaired autophagy-lysosome system. Recently, the
focus has shifted to vesicle trafficking. In this review, we
emphasized the importance of the functions of Rabs and
their potential interplay with different PD-related genes.
Rabs perform an essential role in vesicle trafficking and
cellular homeostasis maintenance. Not only are Rabs closely
associated with α-synuclein-mediated pathological process
but they also interact with many genes whose mutations
or polymorphisms lead to the development of PD. It is
plausible that Rabs could be regarded as novel biomarkers
or therapeutic targets before the clinical manifestation of
PD. However, the role of Rabs in the molecular pathway
of PD remains elusive. More functional studies should be
conducted to reveal the interplay between Rabs and different
effectors.
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